Week in review: BLA accepted for meningococcal vaccine, single-tablet HIV regimen data
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, April 15, to Friday, April 19, 2024), and click on each link to read and watch anything you may have missed.
1.) FDA accepts BLA for meningococcal ABCWY vaccine, target action date set
The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.
Click here for the full article.
2.) Bictegravir, emtricitabine, and tenofovir alafenamide efficacy, safety in children with HIV 2 years and up
The low-dose, coformulated regimen was well tolerated, and overall data supports its use in children with HIV aged 2 years and older weighing between 30.86 lbs (14 kg) and 55.11 lbs (25 kg).
Click here for the full article.
3.) RSV monoclonal antibody nirsevimab to be 5% more expensive
The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.
Click here for the full article.
4.) Reducing elevated non-HDL-C levels in childhood could prevent premature cardiovascular disease
"These findings suggest that primordial and primary interventions to prevent and reduce elevated childhood non–HDL-C levels may help prevent premature CVD," wrote the study authors.
Click here for the full article.
5.) Substance use trends among youth and importance of screenings
In this Contemporary Pediatrics video interview, Angela Nash, PhD, APRN, CPNP-PC, PMHS, associate professor, Cizik School of Nursing Faculty, UT Health Houston, explained the current trends that are being observed among youth in the United States.
